Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel,
AUTOR(ES)
Cury-Martins, Jade; Eris, Adriana Pessoa Mendes; Abdalla, Cristina Martinez Zugaib; Silva, Giselle de Barros; Moura, Veronica Paula Torel de; Sanches, Jose Antonio
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2020-03
RESUMO
Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.
Documentos Relacionados
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe
- Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel
- Neurologic adverse events of cancer immunotherapy
- Pharmacogenetics and ethnically targeted therapies: Authors' reply